Glenmark Pharmaceuticals receives ANDA approval for metronidazole vaginal gel, 0.75%

Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA

Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection

The company has 47 ANDA's pending approval with the U.S.FDA

Glenmark Pharmaceuticals net profit at Rs 306.52 crores in Q1FY22

The company reports revenue growth of 26% and PAT growth of 21% YoY

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.

Glenmark launches generic Methylene Blue Injection in US market

Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America

Glenmark launches Winlevi across key European markets

First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe

Cipla elevates Manoj Dimri as Group Business Head

Pharma industry veteran brings extensive experience in commercial strategy, business growth, and market leadership to his expanded role at Cipla

Glenmark launches generic Lacosamide Injection USP in US Market

Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually

Glenmark posts strong FY26 results with 27.5% revenue jump

Ashish Mukkirwar appointed CFO of Jubilant Pharmova

The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives